Partnering, Pharma

Sellas Clinicals in pharma licensing deal for $531.4 million with Fosun Pharma

Posted on 23 October 2013

Tags: , , ,

Shanghai Fosun Pharma plans to sell ex-China rights for two drug candidates in pharma licensing deal– one treating cancer, the other diabetes – to Sellas Clinicals Holding of Switzerland.

Sellas will pay up to $531.4 million in clinical milestones, based on trials in the US and Europe.

The pharma licensing agreement, which has not been finalized, will be between an indirect subsidiary of Fosun, Chongqing Fochon Pharma, and Sellas.

For further deal information visit Current Agreements (subscription required)


Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary

Report: Oncology Partnering Terms and Agreements

Browse: Complete Current Partnering report catalog

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply